EGFR Y69FS*11

CI-VAR-00004840Explore in graph →CIViC 1672

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Esophageal Squamous Cell Carcinoma1
EGFR Y69FS*11	Erlotinib	Predictive	D	Supports Resistance	—	submitted	EID4808 In an in vitro study, an esophageal squamous cell carcinoma cell line KYSE70 expressing EGFR Y69fs*11 mutation was associated with insensitivity to erlotinib treatment (IC50=4.31uM). Resistance was de… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.